B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Is that the case? Let's look into it and decide whether the company is worth investing in.

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...